Table 1.
Patients enrolled in the START-Register, indication for anticoagulation and type of treatment.
Table 2.
Clinical characteristics of NVAF patients included in the START-Register.
Table 3.
Clinical characteristics of AF patients in relation to stroke and bleeding risk stratification models.
Table 4.
Some characteristics of NVAF patients enrolled in START-Register, compared to those in the GARFIELD Registry and in randomized trials on DOAC.
Table 5.
Number of anticoagulation-naive patients with NVAF who at the moment of inclusion in the START-Register would have been compliant with the lower limit of creatinine clearance declared by the drug companies and with the criteria established from the Italian Regulatory Agency (AIFA), in order to be potentially treated with DOA.
The criterion regarding the individual difficulties in performing the laboratory control of INR, as well as the percentage of time in range (all the START-Register patients were VKA-naive at inclusion) have not been taken into account for this evaluation.